The Pennant Group (NASDAQ:PNTG) Shares Up 8.7% – Still a Buy?

The Pennant Group, Inc. (NASDAQ:PNTG) was up 8.7% during trading on Friday . The company traded as high as $25.87 and last traded at $25.8210. Approximately 108,125 shares traded hands during trading, a decline of 59% from the average daily volume of 262,978 shares. The stock had previously closed at $23.75.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Wells Fargo & Company cut their price objective on The Pennant Group from $31.00 to $29.00 and set an “equal weight” rating for the company in a research report on Thursday, August 14th. Wall Street Zen cut The Pennant Group from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Truist Financial reduced their price target on shares of The Pennant Group from $32.00 to $28.00 and set a “hold” rating on the stock in a research report on Wednesday, July 16th. Stephens restated an “overweight” rating and issued a $40.00 price objective on shares of The Pennant Group in a research report on Thursday, October 9th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of The Pennant Group in a research note on Wednesday. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.80.

The Pennant Group Stock Performance

The firm’s 50-day moving average price is $24.74 and its 200 day moving average price is $25.81. The company has a market cap of $891.06 million, a price-to-earnings ratio of 34.57, a PEG ratio of 2.07 and a beta of 1.39. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.21 and a current ratio of 1.21.

The Pennant Group (NASDAQ:PNTG) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.01. The firm had revenue of $229.04 million for the quarter, compared to analysts’ expectations of $221.96 million. The Pennant Group had a net margin of 3.15% and a return on equity of 9.52%. The Pennant Group has set its FY 2025 guidance at 1.140-1.180 EPS. On average, sell-side analysts anticipate that The Pennant Group, Inc. will post 0.75 EPS for the current year.

Hedge Funds Weigh In On The Pennant Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Van Berkom & Associates Inc. grew its position in shares of The Pennant Group by 10.1% during the 3rd quarter. Van Berkom & Associates Inc. now owns 3,112,812 shares of the company’s stock worth $78,505,000 after buying an additional 284,856 shares during the period. 8 Knots Management LLC raised its position in shares of The Pennant Group by 23.9% in the 1st quarter. 8 Knots Management LLC now owns 3,014,023 shares of the company’s stock valued at $75,803,000 after acquiring an additional 581,313 shares during the period. Ophir Asset Management Pty Ltd boosted its stake in The Pennant Group by 403.9% during the 2nd quarter. Ophir Asset Management Pty Ltd now owns 1,048,759 shares of the company’s stock worth $31,305,000 after acquiring an additional 840,642 shares during the last quarter. Paradigm Capital Management Inc. NY grew its holdings in The Pennant Group by 1.7% during the first quarter. Paradigm Capital Management Inc. NY now owns 955,000 shares of the company’s stock valued at $24,018,000 after purchasing an additional 16,000 shares during the period. Finally, Geode Capital Management LLC grew its holdings in The Pennant Group by 4.6% during the second quarter. Geode Capital Management LLC now owns 832,481 shares of the company’s stock valued at $24,853,000 after purchasing an additional 36,357 shares during the period. Institutional investors own 85.88% of the company’s stock.

The Pennant Group Company Profile

The Pennant Group, Inc provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families.